In summary, these data collectively suggest inhibitors of HIPK2, either inhibiting the kinase activity or its interaction with downstream effectors such as Smad3, would be therapeutically effective against renal fibrosis in CKD. This evidence concerns the gene SMAD3 and chronic kidney disease.